8-K: Allurion Technologies Announces 1-for-25 Reverse Stock Split to Regain NYSE Compliance

Allurion Technologies will implement a 1-for-25 reverse stock split effective January 3, 2025, to increase its stock price and regain compliance with NYSE listing standards.

Summary

• Allurion Technologies has announced a 1-for-25 reverse stock split of its common stock.
• The reverse stock split will be effective on January 3, 2025, at 12:01 a.m. Eastern Time.
• The company's common stock will begin trading on a split-adjusted basis on the New York Stock Exchange (NYSE) at the opening of trading on January 3, 2025.
• The reverse stock split will reduce the number of outstanding shares from approximately 67.78 million to approximately 2.71 million.
• No fractional shares will be issued; instead, shareholders will receive an additional fraction of a share to round up to the next whole share.
• Proportional adjustments will be made to equity incentive plans, stock options, restricted stock units, convertible notes, and warrants.
• The primary goal of the reverse stock split is to increase the market price of the common stock and regain compliance with the NYSE's minimum price requirement of $1.00 per share.

Sentiment

Score: 5

Explanation: The document is neutral in tone, focusing on the mechanics of the reverse stock split. While the action is necessary to maintain listing, it also reflects underlying issues with the stock price. The forward-looking statements are cautious, acknowledging risks and uncertainties.

Positives

• The reverse stock split is intended to increase the stock price, which could help the company regain compliance with NYSE listing standards.
• Shareholders will receive whole shares, with fractional shares rounded up to the next whole share.
• Adjustments to equity plans and convertible securities will maintain the proportional value for holders.

Negatives

• The reverse stock split reduces the number of outstanding shares, which could be perceived negatively by some investors.
• The need for a reverse stock split indicates that the company's stock price has been below the NYSE minimum listing requirement.

Risks

• The company's ability to maintain regulatory approvals and successfully commercialize its products is a risk.
• The timing and results of clinical studies and trials could impact the company's performance.
• The company faces risks related to market competition, intellectual property, and regulatory requirements.
• Global economic conditions and geopolitical events could affect the company's business.
• The company's noncompliance with NYSE continued listing standards may impact the company's results of operations, business operations and reputation and the trading prices and volatility of the company's common stock.

Future Outlook

The company expects the reverse stock split to increase the market price of its common stock and help it regain compliance with NYSE listing standards. However, the company acknowledges that future results are subject to various risks and uncertainties.

Management Comments

• The Board of Directors determined to effect a one-for-twenty five reverse stock split of the Company's common stock.
• The Company believes that the reverse stock split will increase the market price for its Common Stock and cure the deficiency in the Minimum Price Requirement.

Industry Context

Reverse stock splits are often used by companies to avoid delisting from major exchanges when their stock price falls below minimum requirements. This action is not uncommon in the biotech and medical device industries, where companies may experience volatility in their stock price due to clinical trial results, regulatory approvals, and market competition.

Comparison to Industry Standards

• Reverse stock splits are a common mechanism for companies facing delisting from major exchanges, particularly when share prices fall below minimum thresholds.
• Many companies in the biotech and medical device sectors have used reverse stock splits to maintain their listing status, including companies like Cassava Sciences and Ocugen.
• The 1-for-25 ratio is within the typical range for reverse stock splits, which can vary from 1-for-2 to 1-for-100 depending on the specific circumstances and the desired post-split share price.
• The goal of regaining compliance with the NYSE minimum price requirement is a standard objective for companies implementing reverse stock splits.

Stakeholder Impact

• Shareholders will experience a reduction in the number of shares they own, but the value of their holdings should remain proportionally the same.
• The reverse stock split is intended to increase the stock price, which could benefit shareholders if the company regains compliance with NYSE listing standards.
• Employees with stock options or restricted stock units will have their holdings adjusted proportionally.
• The company's ability to maintain its listing on the NYSE could impact its reputation and ability to attract investors.

Next Steps

• The reverse stock split will be effective on January 3, 2025.
• Trading of the common stock will commence on a split-adjusted basis on January 3, 2025.
• Shareholders will see the changes reflected in their accounts on or after January 3, 2025.

Key Dates

Keywords

reverse stock split, NYSE compliance, stock price, common stock, share adjustment, warrants, equity incentive plans, convertible notes, listing standards, Allurion Technologies